Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...
Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...
Ask an AI assistant about your company right now. Don't use a prompt that's meant to get a flattering answer, though; use a real one. Ask it why someone shouldn’t hire you. Ask it what your critics ...
OpenAI is rolling out an early version of an artificial intelligence model meant to speed up drug discoveries, joining a field of growing interest for tech companies eager to prove AI can pave the way ...
Kara Greenberg is a senior news editor for Investopedia, where she does work writing, editing, and assigning daily markets and investing news. Prior to joining Investopedia, Kara was a researcher and ...
Hi, everyone. Let's get started. Welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Priyanka Grover, and I'm part of the JPMorgan Biotech team. Today, our next presenting company is ...
AI on the JVM accelerates: New frameworks like Embabel, Koog, Spring AI, and LangChain4j drive rapid adoption of AI-native and AI-assisted development in Java. Java 25 anchors a modern baseline: The ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results